The Pharmaceutical Market: Ireland

Publisher Name :
Date: 25-Apr-2013
No. of pages:
Inquire Before Buying

THE PHARMACEUTICAL MARKET: IRELAND – REVIEW

Ireland has experienced rapid economic growth over the past 20 years, and has invested in large scale renovation and redevelopment of its healthcare infrastructure. That said, the country is in the midst of a severe economic downturn, with GDP expected to contract in 2012. Due to the recession and Ireland’s huge budget deficit, the country has received an 85 billion euro (US$113 billion) bailout from the EU and IMF. As a result, the government faces an extremely tight financial operating environment in the next few years. It has generally sought to protect healthcare, especially frontline services, from the kinds of cuts experienced elsewhere, but health is not unaffected. A progression of measures has been introduced as the economic position has worsened, most recently the Budget 2011 and related National Recovery Plan.

In March 2011, the government announced plans to introduce Universal Health Insurance (UHI) by 2016. Underpinning the UHI system will be the principle of access according to need and payment according to ability to pay. Insurance with a public or private insurer will be compulsory, with insurance payments related to ability to pay. The government is also planning to remove fees for GP care, which will be implemented in phases, firstly for claimants of free drugs under the Long-Term Illness scheme and the High-Tech Drugs scheme, before being extended to all. Under UHI, public hospitals will no longer be managed by the HSE. They will be independent, not-for-profit trusts with managers accountable to their boards. Hospitals will be paid according to the care they deliver and will be incentivised to deliver more care in a ‘money follows the patient’ system. The government has also reiterated plans to introduce reference pricing and generic substitution, as cost saving measures.

Most global companies have some manufacturing presence in the pharmaceutical market in Ireland. Drugs are either produced in finished form for export, or exported on to other facilities for finishing. A number of branded drugs go off patent in 2012, including Pfizer’s Lipitor and Eli Lilly’s Zyprexa, which could have a negative impact on the industry. However, several multinational companies have been moving into the biologic sector in preparation for the loss of profit from these blockbuster drugs. While the multinational presence is very strong, Ireland has very few domestic producers. In September 2011, Alkermes completed its merger with Elan Drug Technologies (EDT) to form a new company, Alkermes Plc., which is headquartered in Dublin. In September 2011, Pfizer announced it was to invest US$200.0 million at its Grange Castle site, to add two processing suites and to expand current production and product testing capabilities. In September 2011, MSD opened its new R&D centre at its Ballydine site, creating 70 new jobs. Previously, in June 2011, MSD opened two new facilities at the site in Brinny.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

The Pharmaceutical Market: Ireland

Table Of Contents
N/A

  • The Adhesive Paper Industry Looking At a Long Term Bonding
    Adhesives are used extensively in the Paper Industry. They are primarily two kinds ie, the adhesive is either water based or hot melts. The kind of requirement determines the adhesive type in this industry. Adhesives have a wide arena of application. It is used as envelope gums, bookbinding adhesives, for lamination of paper, corrugated adhesives, [...]
  • The Rising Horizon of Maintenance Market of Wind Turbines
    Wind turbines have been one of the most economical means of means of electric production. There are a number of benefits for operating wind turbines. It negates the risk of price factor arising out of dwindling fuel prices and also is independent of pollution and fuel imports. This method of electric production is a capital [...]
  • Liver Fibrosis Market
    Liver Fibrosis is a result of all chronic liver diseases. An extended illness from Liver Fibrosis leads to Cirrhosis of liver and finally liver cancer. It’s a serious disease and one of the world’s rising concern. The medical diagnosis of this disease is very painful and involves a risk of hazards such as severe bleeding [...]
  • Linzess Market All Set To Grow
    Linzess is a therapy for overcoming Irritable Bowel Syndrome with Constipation (IBS-C). The medicine is different and first of its kind that helps a person recover IBS-C. The medicine has some serious side effects so it is important that a person takes the medicine only if prescribed by the doctor. Some of the leading consumers [...]
  • The Steady Ascent of Radiography Systems Industry
    The imaging technique that uses electromagnetic radiation to view internal structures of an human body is popularly known as Radiography. Any radiography that is performed on any other object other than any living being is called industrial radiography. It can be used for treating and detecting a wide range of diseases. Its application ranges from [...]
  • The Market of Plate Heat Exchanger
  • Plate heat exchanger is not only very useful but its also easy to maintain, its compact design makes it more efficient, the product is highly cost-efficient and also the materials of this product are easily available. There are some limitations …

  • The Industry of Binding Machines
  • Binding of books and papers is one of the most important aspect of buying and selling books and thus the demand of binding machines. There are different kinds of binding machines available in the market. The binding type determines the …

  • The Boom In Women Infertility Market
  • Infertility is an abnormality in the regular functioning of the human reproductive system. Anyone of male or female might be suffering from this issue. Infertility in woman is caused by either a genetical factor or factors such as aging or …

  • Retaining the Hard-Won Consumers
  • With the increase in mobile phone usage different operators are coming up with different plan in order to cater to users of all age-group with various data plan to choose from. With the maturing mobile market operators are coming up …

  • To bring in Photography to the Real World Visual Supply Co Acquires Artifact Uprising
  • Visual Supply Co, VSCO has brought a Denver-based startup, Artifact Uprising, which is focused on bringing photographers’ work from the digital hubs on regular basis by modern creatives to the real world as prints and tangible books. Artifact Uprising is …

  • Sudan Pharmaceuticals and Healthcare Report Q1 2015
    Published: 10-Dec-2014        Price: US $1295 Onwards        Pages: 59
    BMI View: The already depreciating Sudanese pound will come under further strain should oil prices continue their decline as oil exports account for around 70% of total exports in the country. We are already forecasting short-term negative growth in US dollar terms for the pharmaceutical market which could come under increased scrutiny should prices decline further. Our long-term outlook is more positive due to the government's plans to develop the pharmaceutical sector and expand access to ......
  • Switzerland Pharmaceuticals and Healthcare Report Q1 2015
    Published: 10-Dec-2014        Price: US $1295 Onwards        Pages: 106
    BMI View: The Swiss government will need to develop policies to maintain the country's long-term attractiveness as a site for clinical trials, especially as we expect cost of conducting clinical research to rise. The drivers of increased attractiveness of non-traditional locations for clinical studies include improving healthcare infrastructure, more and better trained medical professionals, and a growing requirement for local studies in the pharmaceutical approval process. We foresee a cont......
  • Taiwan Pharmaceuticals and Healthcare Report Q1 2015
    Published: 10-Dec-2014        Price: US $1295 Onwards        Pages: 138
    BMI View: Taiwan is one of the most attractive and stable prospects in the region for pharmaceutical and healthcare investment, but is not without flaws. Weaknesses in the country's regulatory regime and drug pricing concerns will continue to deter multinational interest over our forecast period. While our forecasts going into 2015 are unchanged from the previous quarter, BMI believes that Taiwan's export market is poised to benefit greatly from its advantageous position in API manufacturing......
  • Canada Pharmaceuticals and Healthcare Report Q1 2015
    Published: 10-Dec-2014        Price: US $1295 Onwards        Pages: 112
    BMI View: Canada's epidemiological profile will continue to be attractive to manufacturers of medicines for non-communicable diseases. Despite the relatively rapid uptake of innovative pharmaceuticals, the burden of chronic conditions will increase over the next 15 years. Like many other developed states, Canada is introducing cost-containment measures to restrict the commercial opportunities presented to drugmakers. Headline Expenditure Projections ? Pharmaceuticals: CAD25.6bn (USD24.9bn)......
  • Estonia Pharmaceuticals and Healthcare Report Q1 2015
    Published: 10-Dec-2014        Price: US $1295 Onwards        Pages: 104
    BMI View: Despite growing in recent years, the absolute value of the Estonian pharmaceutical market remains small and will continue to remain a marginal market in the Central and Eastern European region. Low-cost generic drugs are prevalent in the market, with doctors obliged to prescribe by international nonproprietary names (INNs), rather than branded names unless there is a specific medical reason for a branded product to be used. Despite the small size of the pharmaceuticals industry, it......
  • France Pharmaceuticals and Healthcare Report Q1 2015
    Published: 10-Dec-2014        Price: US $1295 Onwards        Pages: 131
    BMI View: Despite the French government partially abandoning fiscal deficit targets in its 2015 budget, cost-containment measures will continue to weigh on the pharmaceuticals and healthcare sector for the foreseeable future. The government's strategy of emphasising preventive care and improved access to doctors will likely avoid long-term costs by reducing the burden or risks associated with unchecked conditions. Meanwhile, it will also sustain access to medicines, including prescription dr......
  • Iran Pharmaceuticals and Healthcare Report Q1 2015
    Published: 10-Dec-2014        Price: US $1295 Onwards        Pages: 117
    BMI View: BMI continues to adjust its forecasts for Iran's pharmaceutical market to account for the sanction-induced currency crisis and high rates of inflation. The rapid depreciation of the rial means that we expect the value of the market to contract sharply in US dollar terms. While improved international relations have reduced the regulatory risk associated with operating in the market for multinational drugmakers, the recent proclamation of the Islamic State (IS) in neighbouring Iraq a......
  • Lebanon Pharmaceuticals and Healthcare Report Q1 2015
    Published: 10-Dec-2014        Price: US $1295 Onwards        Pages: 116
    BMI View: The influx of Syrian refugees into Lebanon is putting a strain on the healthcare system, which is unable to meet the additional demand for treatment. Elevated political instability is putting the pharmaceutical sector at risk in terms of government policy relating to healthcare, while a poor economic outlook is detrimental to the ability to pay for medicine. We expect the continuation of the Syrian civil war to hamper growth in this market. Headline Expenditure Projections ? Phar......
  • Myanmar Pharmaceuticals and Healthcare Report Q1 2015
    Published: 10-Dec-2014        Price: US $1295 Onwards        Pages: 64
    BMI View: Non-governmental organisations will continue to expand healthcare access in Myanmar - a boon for the country's pharmaceutical market. However, the country's poor protection of intellectual property, a weak healthcare system and political instability continues to pose high risks and will restrict company revenue streams. Headline Expenditure Projections ? Pharmaceutical sales: MMK324.8bn (USD350mn) in 2013 to MMK387.5bn (USD390mn) in 2014; +19.3% in local currency terms and +11.3%......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs